DKNG is in a sustained, broad-based downtrend: the stock is down 33.85% over the past year and 48.09% year-to-date, with a maximum drawdown of -48.92% and a current price of $18.51 that sits just 8.4% above its 52-week low of $16.55 and 49.9% below its 52-week high of $36.98 — effectively trading in the bottom decile of its annual range. That positioning is characteristic of a falling knife rather than a value setup, because the stock has repeatedly failed to hold rallies and the long-term trend remains decisively negative. The relative strength figures reinforce the damage: -43.54% versus SPY over one year and -55.92% year-to-date, meaning the stock has massively underperformed a market that itself is up 9.69% over twelve months. Short-term momentum is equally poor, with the 1-month change at -3.34% and the 3-month change at -22.97%, and the most recent session was a violent -21.30% single-day collapse from a $23.52 previous close to $18.51 on 69.9 million shares — a volume spike that signals capitulation or a major negative catalyst rather than routine profit-taking. Notably, the 1-month relative strength of +2.05% versus SPY shows the stock had been stabilizing in late October and early November (rallying from $18.59 on October 2 to $23.52 on November 5) before the gap-down erased that entire recovery, a classic failed-rally pattern that argues against calling a bottom. Key technical levels are now well defined: the 52-week low of $16.55 is the critical support, and a breakdown below it would confirm a new leg lower with little visible structural floor, while the $23.50-$24.00 zone that was just lost becomes the first meaningful resistance, followed by the $26-$27 area where the stock repeatedly stalled in July and August. The 52-week high of $36.98 is a distant 100% above the current price and is not a realistic near-term reference. With a short ratio of 2.55, short interest is moderate rather than extreme, so a squeeze-driven rebound is not a high-probability base case, and the absence of a beta in the provided data means position sizing should be anchored to the observed realized volatility — a 21% single-day move and a 48.9% peak-to-trough drawdown imply equity-risk far in excess of the broad market, warranting smaller position sizes and wider stops.

The revenue trajectory is decelerating at the worst possible moment: Q3 2026 revenue of $1.329 billion grew 16.17% year-over-year, but that compares against Q2 2026 revenue of $1.443 billion and Q1 2026 revenue of $1.646 billion, showing sequential contraction of roughly 7.9% from Q2 and 19.3% from Q1 as the business exits the high-hold winter sports calendar. The year-over-year comparison is also unflattering against Q3 2025's $1.144 billion base, and the segment mix — sports at $783.6 million versus product/service/other at $84.5 million — underscores that the sportsbook, the most promotion-sensitive and lowest-margin product, remains the dominant revenue engine. Consensus estimates for roughly $10.15 billion in forward revenue imply meaningful growth from the current run-rate, but the February 2026 guidance miss and the Q3 print suggest the market no longer credits that trajectory at face value. Profitability deteriorated sharply: Q3 2026 net income was -$468.7 million (a -35.27% net margin) versus +$21.1 million in Q1 2026 and +$136.4 million in Q4 2025, and gross margin compressed to 32.28% from 42.32% in Q1 and 45.98% in Q4 2025. The Q3 cost structure is the tell — selling and marketing expense of $605.7 million consumed 45.6% of revenue versus $401.7 million (24.4% of revenue) in Q1 — indicating a promotional and customer-acquisition step-up that management chose to absorb rather than protect margins, and EBITDA swung to -$372.7 million (-28.04% margin) from +$93.4 million in Q1. The trailing gross margin of 41.25% and operating margin of -0.26% confirm the company is only marginally profitable on a trailing basis, and the 0.06% trailing net margin leaves essentially no cushion. Balance sheet and cash flow are the genuine bright spot but come with caveats: trailing free cash flow is +$324.1 million, yet Q3 2026 free cash flow was -$43.7 million and operating cash flow was a mere $25,000, a dramatic reversal from Q2's +$111.4 million operating cash flow and +$106.9 million FCF. The company holds $1.669 billion in cash against a debt-to-equity ratio of 3.06 and a current ratio of just 1.03, so liquidity is adequate but not generous, and the 0.59% ROE is effectively nil. Management is also returning capital — $197.7 million of stock repurchased in Q3 and $122.9 million in Q1 — which is defensible at these depressed prices but competes for cash with the prediction-markets build-out; the combination of negative quarterly FCF, heavy SBC ($86.0 million in Q3), and elevated leverage means the company is not yet self-funding its growth ambitions and remains sensitive to capital-market conditions.